Congenital Hyperinsulinism: Clinical Trials

6 trials for Congenital Hyperinsulinism, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 active not recruiting, 1 recruiting. 6 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 36Completed 4, Active not recruiting 1, Recruiting 1
Phase 21Completed 1

Follow Congenital Hyperinsulinism: new trials by email Literature Review of Congenital Hyperinsulinism trials Research Report on Congenital Hyperinsulinism

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
RZ358 Treatment for Congenital Hyperinsulinism
RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC - Congenital Hyperinsulinism
Phase 3Active not recruitingRezolute562024-01-112026-01-08
18F-DOPA II - PET Imaging Optimization
18F-DOPA, Furosemide Injection - Congenital Hyperinsulinism, Neuroblastoma
Phase 3RecruitingUniversity of Alberta8002021-01-202026-02-09
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
dasiglucagon, Placebo - Congenital Hyperinsulinism
Phase 2 / Phase 3CompletedZealand Pharma122020-06-192025-03-14
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
dasiglucagon - Congenital Hyperinsulinism
Phase 3CompletedZealand Pharma422019-05-022026-08-03
A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Dasiglucagon, Standard of Care - Congenital Hyperinsulinism
Phase 3CompletedZealand Pharma322019-02-072023-12-13
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
18F-DOPA - Congenital Hyperinsulinism, Neuroblastoma
Phase 3CompletedUniversity of Alberta4002017-06-292022-01-10

Narrower conditions

Neuroblastoma (2)  ·  Neuroendocrine Tumors (2)  ·  Parkinson Disease (2)  ·  Brain Neoplasms (1)  ·  Digestive System Diseases (1)  ·  Glucose Metabolism Disorders (1)  ·  Hyperinsulinism (1)  ·  Hypoglycemia (1)  ·  Lewy Body Disease (1)  ·  Metabolic Diseases (1)  ·  Pancreatic Diseases (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6)  ·  Infant, Newborn, Diseases (6)  ·  Nutritional and Metabolic Diseases (6)  ·  Digestive System Diseases (5)  ·  Glucose Metabolism Disorders (5)  ·  Hyperinsulinism (5)  ·  Hypoglycemia (5)  ·  Metabolic Diseases (5)  ·  Pancreatic Diseases (5)  ·  Basal Ganglia Diseases (2)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Movement Disorders (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)

Interventions

dasiglucagon (3)  ·  Standard of Care (2)  ·  fluorodopa F 18 (2)  ·  4-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid (1)  ·  Furosemide (1)

Sponsors

Zealand Pharma (3)  ·  University of Alberta (2)  ·  Rezolute (1)

Countries

Germany (4)  ·  United Kingdom (4)  ·  United States (4)  ·  Israel (3)  ·  Canada (2)  ·  Bulgaria (1)  ·  Denmark (1)  ·  France (1)  ·  Georgia (1)  ·  Greece (1)  ·  Oman (1)  ·  Qatar (1)  ·  Spain (1)  ·  Turkey (Türkiye) (1)  ·  Vietnam (1)

Top investigators

Charlotte Teglman Schioeler (1)  ·  Gopal Saha, MD (1)  ·  Jelena Ivkovic, MD (1)  ·  Jonathan Abele, MD (1)  ·  Jonathan T Abele, MD (1)

NIH funding

2017 (1)